Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: PPARgamma full agonists (pioglitazone and rosiglitazone) are the mainstay drugs for the treatment of type 2 diabetes; however, mechanism-based side effects have limited their full therapeutic potential. In recent years, much progress has been achieved in the discovery and development of selective PPARgamma modulators (SPPARgammaMs) as safer alternatives to PPARgamma full agonists. AREAS COVERED IN THIS REVIEW: This review focuses on the preclinical and clinical data of all the SPPARgammaMs discovered so far, retrieved by searching PubMed, Prous Integrity database and company news updates from 1999 to date. WHAT THE READER WILL GAIN: Here we thoroughly discuss SPPARgammaMs' mode of action, briefly examine new ways to identify superior SPPARgammaMs, and finally, compare and contrast the pharmacological and safety profile of various agents. TAKE HOME MESSAGE: The preclinical and clinical findings clearly suggest that selective PPARgamma modulators have the potential to become the next generation of PPARgamma agonists: effective insulin sensitizers with a superior safety profile to that of PPARgamma full agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 1×
“Studies with several SPPARgMs have mainly focused on four co-regulators/families of co-regulators: NCoR and silencing mediator for retinoid and thyroid hormone receptors (SMRT), the p300 and CREB binding protein (CBP) family, the PPARg co-activator 1 (PGC-1) family and the p160 family, which are composed of three rela…”
BackgroundMetabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 2×
“Furthermore, although SPPARgMs like MEHP, MRL-20, and MRL-24 act as partial agonists, they show different percentage transactivation in different cell lines using the same reporter assay [12,64].”
BackgroundMethodThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“PPARg , the receptor on which extensive research is in progress, has two isoforms: PPARg1, which is expressed in liver, skeletal muscle, cardiac muscle, kidney, intestines, spleen and white adipose tissue, while PPARg2 is expressed in white and brown adipose tissue [6].”
BackgroundRosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537 · cited 1×
“An intervention trial, ADOPT, has also recorded increase in bone fracture risk with rosiglitazone in postmenopausal women [18].”
BackgroundBerger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., & Leibowitz, M. D. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828476 · Cited by 391
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 2×
“At this moment, it is not clear whether adverse effects are due to nonselective full activation of PPARs either alone or in combination, or compound-specific structure-related issues [28,29].”
BackgroundEffect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., & Ikeda, Y. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.908 · Cited by 281
Thiazolidinediones and Heart Failure
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · Diabetes Care · doi:10.2337/dc07-0141 · Cited by 262
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., et al. (2002) · Metabolism · doi:10.1053/meta.2002.30506 · Cited by 235
Cited by
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
“The first such SPPARMγs, INT131 and MK0533, have been shown in preclinical studies to exhibit at least comparable antidiabetic effects to pioglitazone but with an improved adverse event profile [23, 38, 39].”
Background
Metadata
- Authors
- Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-03-31
- Volume
- 19
- Issue
- 4
- Pages
- 489-512
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2126855139
- Cited by
- 59
- References
- 13
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents. https://app.cochat.ai/papers/10.1517/13543781003640169
- The paper
- Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. (2010). Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543781003640169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.